Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.

"Conflict of interests Gavin Cull has received research funding from BeiGene, Acerta, and Glycomimetics; travel, accommodations, and expenses from Glycomimetics. Jan A. Burger has received research funding from Pharmacyclics, Gilead, and BeiGene; and received honoraria from Janssen and AstraZeneca. Stephen Opat has received honoraria from AbbVie, Roche, AstraZeneca, Merck, Gilead, Janssen, and Novartis; has a consulting or advisory role for AbbVie, Roche, AstraZeneca, and Merck; received research funding from BeiGene, Roche, AstraZeneca, Janssen, Merck, Amgen, and Epizyme; and received travel, accommodations, and expenses from Roche. David Gottlieb has equity in Indee; has received honoraria from AbbVie, Link Health Care, Gilead, Merck, Novartis, and Pfizer; and received research funding from Haemaologix. Emma Verner has received research funding from Janssen‐Cilag Pty Ltd. Judith Trotman has received research funding from BeiGene, Roche, Pharmacyclics, Celgene, a Bristol‐Myers Squibb Company, and Takeda. Paula Marlton has had an advisory role for BeiGene, Janssen, AstraZeneca, AbbVie, Roche, Astellas, Novartis, and Gilead. Javier Munoz has received honoraria from Kyowa and Seattle Genetics; has a consulting or advisory role with Pharmacyclics, Bayer, Gilead, Kite Pharma, Pfizer, Janssen, Juno, Celgene, a Bristol‐Myers Squibb Company; Kyowa, Alexion, BeiGene, Fosunkite, Innovent, and Seattle Genetics; has participated in speakers’ bureaus for Gilead, Kite Pharma Kyowa, Bayer, Pharmacyclics, Janssen, Seattle Genetics, Acrotech, BeiGene, Verastem, AstraZeneca, Celgene, a Bristol‐Myers Squibb Company, Genentech, and AbbVie; received research funding from Kite Pharma, Celgene, a Bristol‐Myers Squibb Company, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, and Millennium. Patrick Johnston has nothing to disclose. David Simpson has employment and equity at BeiGene; received honoraria from AbbVie, Janssen, and Roche; received research funding from AbbVie, Amgen, BeiGene, Celgene, a Bristol‐Myers Squibb Company, MSD, Acerta, Pharmacyclics, Sanofi, and GSK; and received funding for travel, accommodations, and expenses from AbbVie. Jennifer C. Stern, Radha Prathikanti, Kenneth Wu and William Novotny have employment and equity at BeiGene. Jane Huang has employment, equity, and leadership at BeiGene. Constantine S. Tam has received research funding from Janssen, AbbVie, BeiGene, Pharmacyclics, and TG Therapeutics."

"We thank study patients, their supporters, and investigators and clinical research staff at study centres. We thank Siminder Kaur Atwal for helping with conducting the study and with data interpretation. The study was funded by BeiGene USA, Inc. Editorial assistance was provided by Alessandra Richardson, PhD, of Bio Connections, LLC, (Chicago, IL), and funded by BeiGene USA, Inc."